Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas P Restifo

Showing results (101-110 of 260) with videos related to

Pageof 26
Sort By:
Scientific Reports|March 30, 2018
The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8<sup>+</sup> T cellsGeoffrey Guittard, Ana Dios-Esponera, Douglas C Palmer, et al.
Seminars in Cancer Biology|April 3, 2002
Assumptions of the tumor 'escape' hypothesisNicholas P Restifo, Paul A Antony, Steven E Finkelstein, et al.
Cancer Immunology, Immunotherapy : CII|February 10, 2011
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cellsShicheng Yang, Luca Gattinoni, Gattinoni Luca, et al.
Genome Research|July 29, 2011
Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1Gangqing Hu, Dustin E Schones, Kairong Cui, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cellsClaudia Wrzesinski, Chrystal M Paulos, Andrew Kaiser, et al.
The Journal of Experimental Medicine|February 17, 2010
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanomaYing Xie, Akgül Akpinarli, Charles Maris, et al.
Blood|January 16, 2008
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigenBeatrice Bolinger, Philippe Krebs, Yinghua Tian, et al.
The Journal of Clinical Investigation|October 28, 2010
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDhanalakshmi Chinnasamy, Zhiya Yu, Marc R Theoret, et al.
The Journal of Clinical Investigation|June 5, 2002
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cellsHelen Y Wang, Tihui Fu, Gang Wang, et al.
Cancer Research|September 18, 2002
Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell functionChristopher E Touloukian, Wolfgang W Leitner, Paul F Robbins, et al.
Pageof 26

Showing results (101-110 of 260) with videos related to

Sort By:
Pageof 26
Scientific Reports|March 30, 2018
The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8<sup>+</sup> T cellsGeoffrey Guittard, Ana Dios-Esponera, Douglas C Palmer, et al.
Seminars in Cancer Biology|April 3, 2002
Assumptions of the tumor 'escape' hypothesisNicholas P Restifo, Paul A Antony, Steven E Finkelstein, et al.
Cancer Immunology, Immunotherapy : CII|February 10, 2011
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cellsShicheng Yang, Luca Gattinoni, Gattinoni Luca, et al.
Genome Research|July 29, 2011
Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1Gangqing Hu, Dustin E Schones, Kairong Cui, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cellsClaudia Wrzesinski, Chrystal M Paulos, Andrew Kaiser, et al.
The Journal of Experimental Medicine|February 17, 2010
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanomaYing Xie, Akgül Akpinarli, Charles Maris, et al.
Blood|January 16, 2008
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigenBeatrice Bolinger, Philippe Krebs, Yinghua Tian, et al.
The Journal of Clinical Investigation|October 28, 2010
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDhanalakshmi Chinnasamy, Zhiya Yu, Marc R Theoret, et al.
The Journal of Clinical Investigation|June 5, 2002
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cellsHelen Y Wang, Tihui Fu, Gang Wang, et al.
Cancer Research|September 18, 2002
Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell functionChristopher E Touloukian, Wolfgang W Leitner, Paul F Robbins, et al.
Pageof 26